- Home
- CALC vs GDTC Comparison
CALC vs GDTC Comparison
Compare CALC & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- GDTC
- Stock Information
- Founded
- CALC 2011
- GDTC 2018
- Country
- CALC United States
- GDTC Singapore
- Employees
- CALC N/A
- GDTC N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- GDTC Health Care
- Exchange
- CALC Nasdaq
- GDTC Nasdaq
- Market Cap
- CALC 26.7M
- GDTC 28.0M
- IPO Year
- CALC N/A
- GDTC 2023
- Fundamental
- Price
- CALC $1.74
- GDTC $2.05
- Analyst Decision
- CALC Strong Buy
- GDTC Buy
- Analyst Count
- CALC 3
- GDTC 1
- Target Price
- CALC $16.33
- GDTC $5.00
- AVG Volume (30 Days)
- CALC 22.8K
- GDTC 9.2K
- Earning Date
- CALC 05-14-2025
- GDTC 01-01-0001
- Dividend Yield
- CALC N/A
- GDTC N/A
- EPS Growth
- CALC N/A
- GDTC N/A
- EPS
- CALC N/A
- GDTC N/A
- Revenue
- CALC N/A
- GDTC $368,838.00
- Revenue This Year
- CALC N/A
- GDTC $5.37
- Revenue Next Year
- CALC N/A
- GDTC N/A
- P/E Ratio
- CALC N/A
- GDTC N/A
- Revenue Growth
- CALC N/A
- GDTC N/A
- 52 Week Low
- CALC $1.43
- GDTC $1.20
- 52 Week High
- CALC $5.97
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CALC 47.92
- GDTC 40.07
- Support Level
- CALC $1.61
- GDTC $2.00
- Resistance Level
- CALC $1.73
- GDTC $2.45
- Average True Range (ATR)
- CALC 0.10
- GDTC 0.12
- MACD
- CALC -0.01
- GDTC -0.02
- Stochastic Oscillator
- CALC 33.33
- GDTC 11.16
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.